Interestingly, KC1 tumours displayed significantly elevated expression of DUSP4/6 and ETV4, key determinants of sensitivity to MEK1/2 inhibitors (MEKi) (Figures 6A and S14A).58, 59. The gene discussed is MAP2K1; the disease is neoplasm.